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When planning and executing a clinical study, all 
sources of bias should be minimized, from the project’s 
propositions to the written conclusions after the 
observations. In clinical researching scenarios, “blinding” 
involves approaches used to reduce bias after the 
randomization process. Not only the patients, but all 
subjects involved in the research may be kept unaware 
of the treatment group in which patients are alloca-
ted(1,2). An investigation on “mesmerism” was one of the 
earliest experiments using “blinding”. A commission 
that included Benjamin Franklin, appointed by Louis 
XVI in 1784, assessed the real healing effects of this me-
thod. Their placebo controlled blind trials proved that 
the Mesmer’s universal fluid could not cure people and 
that imagination and imitation were the real causes of 
the observed effects (3).
Randomization minimizes differences between treat-
ment groups, but it does not prevent differential group 
and outcome assessments, resulting in potential biased 
estimations of treatment effects; and, hence, biased 
results and conclusions. Thus, an optimal strategy to 
minimize bias is to blind as many individuals as possi-
ble who are working in a trial(4). It is important to point 
that allocation concealment differs from “blinding”; 
the first eliminates selection bias during the process 
of recruitment and randomization, whereas “blinding” 
intends to reduce performance and ascertainment bias 
after randomization(5).
When a clinical study is not blinded, some threats 
may influence the internal validity of the trial, such as: 
changes in the patient’s compliance, increased dropouts 
(especially when the patient knows his/her allocation in 
the control group), loss of the placebo effect (usually 
in the control group), co-intervention (patients from the 
control group seek adjunct treatments to minimize 
the lack of perceived treatment success), influence on 
the side effects and efficacy reports of the outcomes, 
partiality in the evaluation of the outcome of interest, 
favoring one of the groups (the observers’ behaviors are 
influenced by their belief), unequal care provisions from 
the staff, and increasing the study’s subjectivity(2).
“Blinding” can be applied to people involved in diffe-
rent research processes. The most important levels of 
“blinding” are: a) Simple - the participants (allocated 
to the treatment); b) Double – the participants and the 
investigators (the professionals who provide the in ter-
vention); c) Triple – participants, investigators and other 
people involved in data collection, data analysis, finan-
cing, and manuscript writing(2)
The process of “blinding” must consider that both 
interventions cannot be distinguishable by blinded 
individuals. For example, in the case of eye drops, the 
bottle’s format and color, appearance of the solution, 
frequency of instillation, and ocular sensation should 
ideally be the same. In the case of tablets, weight, odor, 
and touch should also be considered. Concerning the 
side effects, some of them should also be present on the 
placebo group (in this cases the placebo group is known 
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as active placebo). The route of administration must 
also be considered. If the interventions being compared 
have different routes of administration, or if a new drug 
will be compared with a standard treatment already in 
use, a double dummy design(6), in which one drug and 
one placebo for each group exist, should be applied. 
Although all described precautions should be taken to 
promote “blinding”, they need to be uncovered in some 
trials with robust inadvertent results or new highly ad-
vantageous treatment options(7). In rehabilitation trials, 
in which the outcomes are measured using subjectivity, 
such as quality of life or pain level, the blinding pro-
cess is particularly ineffective. That is why objective 
outcomes are always preferred. Indeed, randomized 
controlled trials of surgical interventions are frequently 
more difficult to blind than trials using medications. It 
may be possible for researchers to blind other members 
of the treatment team; and, thus, limit the potential for 
differential treatment. As no analytical techniques can 
correct a drawback due to treatment selection or assess-
ment of outcomes and results from unblinded trials, 
they need to be interpreted with caution(5). Besides, re-
searches should be aware of some disadvantages of the 
blinding process, including increased costs, the need for 
more researchers involved, ethical and logistic issues, 
and the fact that the study may not reflect a real health 
care approach in specific trials.
The use of the “masked” approach as an alternative to 
“blinded” one in ophthalmology may be considered “far too 
precious” to non-ophthalmologists, as pointed out Morris 
and Fraser(8). However, those authors justify its use with a 
s cenario in which an elderly woman with age-rela ted ma-
cular degeneration, invited to a double-blinded macular 
study, may be terrified and withdraw the trial due to the 
“chance of becoming blind” related to the experiment. 
Thus, in eye studies, some researchers prefer the term 
“masked” to “blinded,” to avoid a term that denotes one 
of the potential, unfortunate outcomes in an ophthalmic 
trial. Schulz et al.(4) argued that the inappropriate use of 
the “blinding” terminology in ophthalmological settings 
should not dictate the use of the term “masking” for all 
other randomized trials.
Finally, “blinding” must be considered one of the hall-
marks of methodological quality and is largely encouraged 
in clinical trials. Researchers are encouraged to inform 
the “blinding” status of the whole team involved in the 
trial, complying with the CONSORT recommendations(1), 
when practically and ethically possible.
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